Table 2.
Initial immunosuppression characteristics in the two groups
| Variables | Short surviving group (228, 46.4%) | Long surviving group (n = 263, 53.6%) | P value |
|---|---|---|---|
| N (%) or median (IQR) | |||
| Induction | |||
| Steroids | 220 (96.5) | 256 (97.3) | 0.61 |
| Immunoglobulins (any) | 71 (31.1) | 64 (24.3) | 0.11 |
| Basiliximab | 0 (–) | 6 (2.3) | 0.03 |
| ATG | 48 (21.1) | 37 (14.1) | 0.04 |
| Muromonab-CD3 | 23 (10.1) | 21 (8.0) | 0.43 |
| Maintenance therapy | |||
| CNI* | 199 (87.3) | 255 (97.0) | < 0.0001 |
| Cyclosporine | 128 (56.1) | 145 (55.1) | 0.86 |
| Tacrolimus | 82 (36.0) | 123 (46.8) | 0.02 |
| Twice daily | 82 (36.0) | 123 (46.8) | 0.02 |
| Once daily | 2 (0.9) | 14 (5.3) | 0.009 |
| mTor inhibitor | 0 (–) | 3 (1.1) | 0.25 |
| Azathioprine | 78 (34.2) | 71 (27.0) | 0.09 |
| Derivates of mycophenolic acid | 84 (36.8) | 156 (59.3) | < 0.0001 |
N number, IQR interquartile ranges, ATG antibodies anti-thyroglobulin, CD cluster of differentiation, CNI calcineurin inhibitor, mTOR mammalian target of rapamycin
*Some patients switched during the transplant hospital stay and therefore had multiple drugs concerning the conventional induction + triple maintenance therapy